Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.

Background: ALLEGRO-LT is an ongoing, long-term, open-label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA).

Objectives: To evaluate ritlecitinib safety and efficacy through Month 24 in patients with AA and ≥25% scalp hair loss.

Methods: ALLEGRO-LT enrolled rollover patients who previously received study intervention in either ALLEGRO phase 2a or 2b/3 studies and de novo patients who had not received treatment in either study.

Speech-Language Pathologists' Experiences Working With Culturally and Linguistically Diverse Families: A Scoping Review.

Introduction: Evidence-based practices (EBPs) use evidence (external and internal), clinician expertise, and client/caregiver perspectives to deliver effective, individualized care. Each component of EBP is highly relevant and most effective when implemented together. Families with cultural or linguistic backgrounds different from the mainstream experience inequitable treatment across all disciplines.

Sublingual Minoxidil Increases Fibre Diameter in Male Androgenetic Alopecia. - A proxy for Reversal of Hair Follicle Miniaturization.

Background: The histological hallmark of male androgenetic alopecia (MAGA) is transformation of terminal follicles into miniaturized secondary-vellus follicles. As the volume of the dermal papilla determines the size of the hair bulb and hair fibre diameter, any treatment induced increase in fibre diameter could be used as a proxy for reversal of hair follicle miniaturization. While clinical trials with minoxidil topical solution in MAGA do not demonstrate increased fibre diameter, vellus-to-terminal reconversion is shown in a humanized mouse model treated with MXL.